Bounded definition
A process in which cells are collected, edited and assessed outside the body, then returned under a clinical or experimental protocol.
What the cited work establishes
The report describes ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early clinical outcomes for two participants under a specific investigational protocol.
The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Claims: urn:maha:claim:ex-vivo-genome-editing-workflow
What remains a separate question
The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific.
Two early cases do not establish population-level safety, durability, comparative effectiveness, or general readiness of genome editing.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
Somatic versus germline genome editing
outbound connection · comparison
The reported ex-vivo intervention edits somatic hematopoietic cells rather than reproductive-line cells.
Cell-line versus primary-cell evidence
outbound connection · comparison
The cell product is composed of participant-derived primary cells, not an immortalized line.
Somatic versus germline genome editing
inbound connection · comparison
The cited ex-vivo hematopoietic workflow targets somatic cells and is not a germline intervention.
Claim ledger
Every proposition keeps its own evidence state.
The cited report describes collection, ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early follow-up for two participants.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
- Boundary
- The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · The New England Journal of Medicine
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Haydar Frangoul, David Altshuler, M. Domenica Cappellini, Yi-Shan Chen, et al.
- Exact locator
- Abstract; Methods; Results; figures and tables for the two reported participants; supplementary protocol.
- Establishes
- The report describes ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early clinical outcomes for two participants under a specific investigational protocol.
- Boundary
- Two early cases do not establish population-level safety, durability, comparative effectiveness, or general readiness of genome editing.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The study was sponsored by CRISPR Therapeutics and Vertex Pharmaceuticals; author relationships are disclosed in the article.